Literature DB >> 24865424

Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression.

Roberto Ferrarese, Griffith R Harsh, Ajay K Yadav, Eva Bug, Daniel Maticzka, Wilfried Reichardt, Stephen M Dombrowski, Tyler E Miller, Anie P Masilamani, Fangping Dai, Hyunsoo Kim, Michael Hadler, Denise M Scholtens, Irene L Y Yu, Jürgen Beck, Vinodh Srinivasasainagendra, Fabrizio Costa, Nicoleta Baxan, Dietmar Pfeifer, Dominik von Elverfeldt, Rolf Backofen, Astrid Weyerbrock, Christine W Duarte, Xiaolin He, Marco Prinz, James P Chandler, Hannes Vogel, Arnab Chakravarti, Jeremy N Rich, Maria S Carro, Markus Bredel.   

Abstract

Tissue-specific alternative splicing is critical for the emergence of tissue identity during development, yet the role of this process in malignant transformation is undefined. Tissue-specific splicing involves evolutionarily conserved, alternative exons that represent only a minority of the total alternative exons identified. Many of these conserved exons have functional features that influence signaling pathways to profound biological effect. Here, we determined that lineage-specific splicing of a brain-enriched cassette exon in the membrane-binding tumor suppressor annexin A7 (ANXA7) diminishes endosomal targeting of the EGFR oncoprotein, consequently enhancing EGFR signaling during brain tumor progression. ANXA7 exon splicing was mediated by the ribonucleoprotein PTBP1, which is normally repressed during neuronal development. PTBP1 was highly expressed in glioblastomas due to loss of a brain-enriched microRNA (miR-124) and to PTBP1 amplification. The alternative ANXA7 splicing trait was present in precursor cells, suggesting that glioblastoma cells inherit the trait from a potential tumor-initiating ancestor and that these cells exploit this trait through accumulation of mutations that enhance EGFR signaling. Our data illustrate that lineage-specific splicing of a tissue-regulated alternative exon in a constituent of an oncogenic pathway eliminates tumor suppressor functions and promotes glioblastoma progression. This paradigm may offer a general model as to how tissue-specific regulatory mechanisms can reprogram normal developmental processes into oncogenic ones.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24865424      PMCID: PMC4071411          DOI: 10.1172/JCI68836

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  97 in total

1.  A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes.

Authors:  H X Liu; L Cartegni; M Q Zhang; A R Krainer
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

Review 2.  Listening to silence and understanding nonsense: exonic mutations that affect splicing.

Authors:  Luca Cartegni; Shern L Chew; Adrian R Krainer
Journal:  Nat Rev Genet       Date:  2002-04       Impact factor: 53.242

3.  Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain.

Authors:  Marta C Nunes; Neeta Singh Roy; H Michael Keyoung; Robert R Goodman; Guy McKhann; Li Jiang; Jian Kang; Maiken Nedergaard; Steven A Goldman
Journal:  Nat Med       Date:  2003-03-10       Impact factor: 53.440

4.  Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells.

Authors:  P O-charoenrat; H Modjtahedi; P Rhys-Evans; W J Court; G M Box; S A Eccles
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

5.  Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.

Authors:  P Kunkel; U Ulbricht; P Bohlen; M A Brockmann; R Fillbrandt; D Stavrou; M Westphal; K Lamszus
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

6.  Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia.

Authors:  A Maity; N Pore; J Lee; D Solomon; D M O'Rourke
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

7.  ANX7, a candidate tumor suppressor gene for prostate cancer.

Authors:  M Srivastava; L Bubendorf; V Srikantan; L Fossom; L Nolan; M Glasman; X Leighton; W Fehrle; S Pittaluga; M Raffeld; P Koivisto; N Willi; T C Gasser; J Kononen; G Sauter; O P Kallioniemi; S Srivastava; H B Pollard
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-03       Impact factor: 11.205

8.  Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences.

Authors:  Qiang Xu; Christopher Lee
Journal:  Nucleic Acids Res       Date:  2003-10-01       Impact factor: 16.971

9.  PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter.

Authors:  Nabendu Pore; Shuang Liu; Daphne A Haas-Kogan; Donald M O'Rourke; Amit Maity
Journal:  Cancer Res       Date:  2003-01-01       Impact factor: 12.701

10.  Haploinsufficiency of Anx7 tumor suppressor gene and consequent genomic instability promotes tumorigenesis in the Anx7(+/-) mouse.

Authors:  Meera Srivastava; Cristina Montagna; Ximena Leighton; Mirta Glasman; Shanmugam Naga; Ofer Eidelman; Thomas Ried; Harvey B Pollard
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-07       Impact factor: 11.205

View more
  45 in total

1.  Ubiquitin-protein ligase E3C promotes glioma progression by mediating the ubiquitination and degrading of Annexin A7.

Authors:  Si-Jian Pan; Shi-Kun Zhan; Wei-Zhong Ji; Yi-Xin Pan; Wei Liu; Dian-You Li; Peng Huang; Xiao-Xiao Zhang; Chun-Yan Cao; Jing Zhang; Liu-Guan Bian; Bomin Sun; Qing-Fang Sun
Journal:  Sci Rep       Date:  2015-06-11       Impact factor: 4.379

Review 2.  Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes.

Authors:  A Sveen; S Kilpinen; A Ruusulehto; R A Lothe; R I Skotheim
Journal:  Oncogene       Date:  2015-08-24       Impact factor: 9.867

3.  Long noncoding RNA H19 interacts with polypyrimidine tract-binding protein 1 to reprogram hepatic lipid homeostasis.

Authors:  Chune Liu; Zhihong Yang; Jianguo Wu; Li Zhang; Sangmin Lee; Dong-Ju Shin; Melanie Tran; Li Wang
Journal:  Hepatology       Date:  2018-03-25       Impact factor: 17.425

Review 4.  Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.

Authors:  Nidhi Jyotsana; Michael Heuser
Journal:  Expert Opin Ther Targets       Date:  2017-12-20       Impact factor: 6.902

5.  Isorhapontigenin suppresses growth of patient-derived glioblastoma spheres through regulating miR-145/SOX2/cyclin D1 axis.

Authors:  Zhou Xu; Xingruo Zeng; Jiawei Xu; Derek Xu; Jingxia Li; Honglei Jin; Guosong Jiang; Xiaosi Han; Chuanshu Huang
Journal:  Neuro Oncol       Date:  2015-12-17       Impact factor: 12.300

6.  MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.

Authors:  Shile Zhang; Jun S Wei; Samuel Q Li; Tom C Badgett; Young K Song; Saurabh Agarwal; Cristian Coarfa; Catherine Tolman; Laura Hurd; Hongling Liao; Jianbin He; Xinyu Wen; Zhihui Liu; Carol J Thiele; Frank Westermann; Shahab Asgharzadeh; Robert C Seeger; John M Maris; Jamie M Guidry Auvil; Malcolm A Smith; Eric D Kolaczyk; Jason Shohet; Javed Khan
Journal:  Cancer Lett       Date:  2015-12-10       Impact factor: 8.679

7.  Epigenetic Regulation of ZBTB18 Promotes Glioblastoma Progression.

Authors:  Vita Fedele; Fangping Dai; Anie P Masilamani; Dieter H Heiland; Eva Kling; Ana M Gätjens-Sanchez; Roberto Ferrarese; Leonardo Platania; Doostkam Soroush; Hyunsoo Kim; Sven Nelander; Astrid Weyerbrock; Marco Prinz; Andrea Califano; Antonio Iavarone; Markus Bredel; Maria S Carro
Journal:  Mol Cancer Res       Date:  2017-05-16       Impact factor: 5.852

8.  RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML.

Authors:  Leslie A Crews; Larisa Balaian; Nathaniel P Delos Santos; Heather S Leu; Angela C Court; Elisa Lazzari; Anil Sadarangani; Maria A Zipeto; James J La Clair; Reymundo Villa; Anna Kulidjian; Rainer Storb; Sheldon R Morris; Edward D Ball; Michael D Burkart; Catriona H M Jamieson
Journal:  Cell Stem Cell       Date:  2016-08-25       Impact factor: 24.633

9.  The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma.

Authors:  Guillermo Aldave; Marisol Gonzalez-Huarriz; Angel Rubio; Juan Pablo Romero; Datta Ravi; Belén Miñana; Mar Cuadrado-Tejedor; Ana García-Osta; Roeland Verhaak; Enric Xipell; Naiara Martinez-Vélez; Arlet Acanda de la Rocha; Montserrat Puigdelloses; Marc García-Moure; Miguel Marigil; Jaime Gállego Pérez-Larraya; Oskar Marín-Bejar; Maite Huarte; Maria Stella Carro; Roberto Ferrarese; Cristobal Belda-Iniesta; Angel Ayuso; Ricardo Prat-Acín; Fernando Pastor; Ricardo Díez-Valle; Sonia Tejada; Marta M Alonso
Journal:  Neuro Oncol       Date:  2018-06-18       Impact factor: 12.300

Review 10.  Uncovering the roles of long noncoding RNAs in neural development and glioma progression.

Authors:  Alexander D Ramos; Frank J Attenello; Daniel A Lim
Journal:  Neurosci Lett       Date:  2015-12-28       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.